Pfizer in gene therapy deal

Pfizer Inc has expanded its portfolio of gene therapy assets following a licensing deal with Sangamo Therapeutics Inc giving it exclusive rights to a preclinical product for haemophilia A, a bleeding disorder caused by the lack of clotting factor VIII.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States